Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Protalix BioTherapeutics (PLX) Long-Term Debt Repayments (2017 - 2021)

Protalix BioTherapeutics' quarterly Long-Term Debt Repayments came in at $4.0 million in Q4 2021, down 81.53% quarter-over-quarter from $21.9 million in Q3 2021.

Protalix BioTherapeutics has reported Long-Term Debt Repayments for 4 years, with the latest figure at $4.0 million in Q4 2021.

  • For the quarter ending Q4 2021, Long-Term Debt Repayments changed N/A year-over-year to $4.0 million; the trailing twelve-month figure through Dec 2024 stood at $26.0 million (changed N/A YoY), and the FY2024 full-year result was $20.4 million, changed N/A from the prior year.
  • Long-Term Debt Repayments for Q4 2021 stood at $4.0 million, down from $21.9 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $21.9 million in Q3 2021, with the low at $11668.0 in Q1 2018.
  • Average Long-Term Debt Repayments over 4 years is $5.7 million, with a median of $4.0 million recorded in 2021.
  • Year-over-year, Long-Term Debt Repayments sank 99.83% in 2018 and jumped 4993.95% in 2021.
  • Tracing PLX's Long-Term Debt Repayments over 4 years: stood at $6.7 million in 2017, then slumped by 62.38% to $2.5 million in 2018, then sank by 83.0% to $430000.0 in 2020, then soared by 840.93% to $4.0 million in 2021.
  • The last three Long-Term Debt Repayments figures came in at $4.0 million (Q4 2021), $21.9 million (Q3 2021), and $4.1 million (Q1 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Protalix BioTherapeutics 164.49 Mn 153.70 Mn 29.62 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 4.05 Mn
Dec 31, 2021 4.05 Mn
Sep 30, 2021 21.90 Mn
Sep 30, 2021 21.90 Mn
Mar 31, 2021 4.09 Mn
Mar 31, 2021 4.09 Mn
Sep 30, 2020 430,000.00
Sep 30, 2020 430,000.00
Jun 30, 2018 2.53 Mn
Jun 30, 2018 2.53 Mn
Mar 31, 2018 11,668.00
Mar 31, 2018 11,668.00
Mar 31, 2017 6.73 Mn
Mar 31, 2017 6.73 Mn